Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study-Reference-Cited by-同舟云学术

Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study

Published:2015-11 Issue:15 Volume:16 Page:1506-1514
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Efficace Fabio,Gaidano Gianluca,Breccia Massimo,Voso Maria Teresa,Cottone Francesco,Angelucci Emanuele,Caocci Giovanni,Stauder Reinhard,Selleslag Dominik,Sprangers Mirjam,Platzbecker Uwe,Ricco Alessandra,Sanpaolo Grazia,Beyne-Rauzy Odile,Buccisano Francesco,Palumbo Giuseppe A,Bowen David,Nguyen Khanh,Niscola Pasquale,Vignetti Marco,Mandelli Franco

Publisher

Elsevier BV

Subject

Oncology

Reference30 articles.

1. Myelodysplastic syndromes;Ades;Lancet,2014

2. Prognostic models in myelodysplastic syndromes;Bejar;Hematology Am Soc Hematol Educ Program,2013

3. International scoring system for evaluating prognosis in myelodysplastic syndromes;Greenberg;Blood,1997

4. The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients;Stauder;Ann Hematol,2012

5. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet;Malcovati;Blood,2013

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS);HemaSphere;2024-05

2. Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial;The Lancet;2024-01

3. Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice;Journal of Personalized Medicine;2023-11-28

4. Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS);Blood Reviews;2023-11